The outcome of infarct healing in mice strongly depends on genetic background. On the basis of our results, we suggest that for studies on infarct rupture, the 129S6 mouse is the background of choice, whereas BalbC and Swiss mice are the preferred models to study infarct thinning post-MI.
Abstract-The hypertrophic response of the heart has been recognized recently as the net result of activation of prohypertrophic and antihypertrophic pathways. Here we report the involvement of the Wnt/Frizzled pathway in the onset of cardiac hypertrophy development. Stimulation of the Wnt/Frizzled pathway activates the disheveled (Dvl) protein. Disheveled subsequently can inhibit glycogen synthase kinase-3, a protein with potent antihypertrophic actions through diverse molecular mechanisms. In the Wnt/Frizzled pathway, inhibition of glycogen synthase kinase-3 leads to an increased amount of -catenin, which can act as a transcription factor for several hypertrophy-associated target genes. In this study we subjected mice lacking the Dvl-1 gene and their wild-type littermates to thoracic aortic constriction for 7, 14, and 35 days. In mice lacking the Dvl-1 gene, 7 days of pressure overload-induced increases in left ventricular posterior wall thickness and expression of atrial natriuretic factor and brain natriuretic protein were attenuated compared with their wild-type littermates. -Catenin protein amount was reduced in the group lacking the Dvl-1 gene, and an increased glycogen synthase kinase-3 activity was observed. Moreover, the increase in the amount of Ser 473 -phosphorylated Akt, a stimulator of cardiac hypertrophy, was lower in the group lacking the Dvl-1 gene.In conclusion, we have demonstrated that interruption of Wnt signaling in the mice lacking the Dvl-1 gene attenuates the onset of pressure overload-induced cardiac hypertrophy through mechanisms involving glycogen synthase kinase-3 and Akt. Therefore, the Wnt/Frizzled pathway may provide novel therapeutic targets for antihypertrophic therapy. Key Words: hypertrophy Ⅲ Wnt Ⅲ cell signaling Ⅲ glycogen synthase kinase-3 Ⅲ Akt C ardiac hypertrophy is an adaptive response of the heart to an increased workload, caused by a variety of pathological stimuli, including hypertension, myocardial infarction, and valvular disease. Because cardiomyocytes are terminally differentiated, these cells can only respond by hypertrophic growth. 1 This growth is initially beneficial but a sustained hypertrophic response often leads to heart failure. 2 In this hypertrophic response, extracellular stimulation is translated into a cellular response, leading to changes in the contractile apparatus and to an activation of many signaling pathways. 3 Several of these signaling pathways transduce prohypertrophic signals, but it has been shown that a number of endogenous molecules can regulate the hypertrophic response negatively. 4 One of the most powerful negative regulators that can antagonize the hypertrophic response is glycogen synthase kinase-3 (GSK-3), a ubiquitous serine/threonine protein kinase. 4,5 GSK-3 is a downstream regulatory switch of multiple signaling pathways that regulates a wide range of cellular functions. 6 Dysregulation of GSK-3 plays a role in many human diseases, including diabetes, Alzheimer's disease, bipolar disorder, cancer, 7 and heart failur...
People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.